Carlos Axel López-Pérez1, Xochitl Franco-Mojica1, Ricardo Villanueva-Gaona1, Alexandra Díaz-Alba1,2, Marco Antonio Rodríguez-Florido3, Victor Garcia Navarro4,5. 1. Instituto Tecnológico y de Estudios Superiores de Monterrey Campus Guadalajara, Zapopan, Mexico. 2. Instituto Oncológico Nacional: ION, Guadalajara, Jalisco, Mexico. 3. Unit of Medical Research in Neurological Diseases, Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Mexico City, Mexico. 4. Instituto Tecnológico y de Estudios Superiores de Monterrey Campus Guadalajara, Zapopan, Mexico. garcianavarrov@tec.mx. 5. Instituto Neurológico de Guadalajara S.C, Guadalajara, Jalisco, Mexico. garcianavarrov@tec.mx.
Abstract
INTRODUCTION: Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas first recognized as a new entity in the 2016 World Health Organization Classification of Central Nervous System (CNS) Tumors as DMG H3 K27M-mutant, recently renamed in the new 2021 WHO classification. The aim of this review is to describe the characteristics of diffuse midline gliomas H3 K27-altered in the adult population. METHODS: We performed a review of the current literature regarding the genetic, clinical, imaging characteristics and management of diffuse midline gliomas H3 K27-altered in adult patients. RESULTS: The 2021 WHO classification now designates the previously recognized DMG H3K27M-mutant as DMG H3 K27-altered, recognizing the alternative mechanisms by which the pathogenic pathway can be altered. Thus, the diagnostic criteria for this entity consist of diffuse growth pattern, midline anatomic location, and H3 K27-specific neuroglial mutations. DMGs' characteristic midline location makes them difficult to surgically resect and biopsy, carrying high mortality and morbidity rates, with median survival ranging from 9 to 12 months in adult patients. CONCLUSION: The diagnosis of DMGs H3 K27-altered in adult patients should be considered upon neurological symptoms associated with an infiltrative midline brain tumor detected on imaging. Future studies are necessary to continue refining their characteristics in this age group.
INTRODUCTION: Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas first recognized as a new entity in the 2016 World Health Organization Classification of Central Nervous System (CNS) Tumors as DMG H3 K27M-mutant, recently renamed in the new 2021 WHO classification. The aim of this review is to describe the characteristics of diffuse midline gliomas H3 K27-altered in the adult population. METHODS: We performed a review of the current literature regarding the genetic, clinical, imaging characteristics and management of diffuse midline gliomas H3 K27-altered in adult patients. RESULTS: The 2021 WHO classification now designates the previously recognized DMG H3K27M-mutant as DMG H3 K27-altered, recognizing the alternative mechanisms by which the pathogenic pathway can be altered. Thus, the diagnostic criteria for this entity consist of diffuse growth pattern, midline anatomic location, and H3 K27-specific neuroglial mutations. DMGs' characteristic midline location makes them difficult to surgically resect and biopsy, carrying high mortality and morbidity rates, with median survival ranging from 9 to 12 months in adult patients. CONCLUSION: The diagnosis of DMGs H3 K27-altered in adult patients should be considered upon neurological symptoms associated with an infiltrative midline brain tumor detected on imaging. Future studies are necessary to continue refining their characteristics in this age group.
Authors: Brent Holmes; Angelica Benavides-Serrato; Jacquelyn T Saunders; Kenna A Landon; Adam J Schreck; Robert N Nishimura; Joseph Gera Journal: J Neurooncol Date: 2019-08-31 Impact factor: 4.130
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: M S Aboian; D A Solomon; E Felton; M C Mabray; J E Villanueva-Meyer; S Mueller; S Cha Journal: AJNR Am J Neuroradiol Date: 2017-02-09 Impact factor: 3.825
Authors: David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 13.029
Authors: Changhee Park; Tae Min Kim; Jeong Mo Bae; Hongseok Yun; Jin Wook Kim; Seung Hong Choi; Soon-Tae Lee; Joo Ho Lee; Sung-Hye Park; Chul-Kee Park Journal: Cancer Res Treat Date: 2020-11-09 Impact factor: 4.679